VPRIV: payments to doctors
Payments that named VPRIV as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $613K
- Providers
- 2,826
- Transactions
- 4,795
- Average per transaction
- $128
The per-transaction average — $128 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,826 providers the average total is $217, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Shire North American Group Inc | $322,760 | 52.6% |
| Takeda Pharmaceuticals U.S.A., Inc. | $267,928 | 43.7% |
| Takeda Pharmaceutical Company, Limited | $22,809 | 3.7% |